PF 5180999

Drug Profile

PF 5180999

Alternative Names: modified release PF-05180999; MR PF-05180999; PF-05180999; PF-5180999; PF-999

Latest Information Update: 04 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antimigraines; Antipsychotics; Small molecules
  • Mechanism of Action Type 2 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Migraine; Schizophrenia

Most Recent Events

  • 07 Aug 2014 Discontinued - Phase-I for Migraine (In volunteers) in USA (PO)
  • 01 Dec 2013 Phase-I clinical trials in Migraine (in volunteers) in USA (PO)
  • 28 Feb 2013 Discontinued - Phase-I for Schizophrenia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top